Worth a medium investment for the mid term. A bit later then usual (okt - dec)! It's now low cap season and they are catching up the big ones! And maybe this was a hint? QUALIGEN THERAPEUTICS INC FILES FOR PROSPECTUS BY THE SELLING STOCKHOLDER OF UP TO 5.2 MILLION SHARES OF COMMON STOCK- SEC FILING Source: (bit.ly) NO investment advise by any means :-). Just a hunch!
Bought QLGN on 08 March for 0.56 per share, still holding my shares. RSI on the daily found support on 50 and the weekly is above 30 curling up nicely. Expect this to go to $0.90.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer...
Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene...
As long as it holds 1.8ish, PT1 =8, PT2=16 Crap stock, but it should repeat it's pattern
Qualigen Therapeutics Inc (NASDAQ:QLGN) I think this stock will post a sharp rally from current levels following the earnings report on Friday after-hours. The company announced a revenue increase of 30% from last year and cash equivalents approximately $21.9 Million, providing sufficient runway to accomplish Key Inflection Points (no offerings needed). This was a...
DISCLAIMER This is in no way, shape or form, fluid and function, an analytical, qualitative or intelligent compte rendu. I am obviously not rich, so obviously I haven't made it with my own thinking, so definitely don't put faith in me. But maybe read and learn some things about a company that may or may not make some major moves. Thesis/TL;DR This is the...
This chart position is crazy. Lots of drama in the stock prior. But looks to be primed to breakout soon.
QLGN The price is retesting the neckline of the inverted head and shoulder . It is potentially a very good support for a long entry. I'm playing the bounce with the red line as target (swing trade). I'll close the trade if we break below the neckline. Trade safe.
Hello tradingview community. This is my first post here so hopefully will get better as time goes on. I feel thus is getting primed to take off soon. Maybe as soon as Tomorrow February 1 2021. I see a good setup going and candle formation. I dont know how to explain it yet but I can "see" it happening if we open green tomorrow. Follow along for my updates on...
$QLGN has had a rough couple of months but the downtrend appears to be shifting. I feel that QLGN is undervalued fundamentally and has upside from here. This is not financial advice.
Qualigen Therapeutics Inc (NASDAQ:QLGN) has achieved a boost during Friday’s market as traders witnessed the oversold condition, driving shares up 2.83%. I would like to see a break over yesterday's high of 3.33 to indicate possible bounce is on deck. I feel that fundamentally, the stock looks attractive at least for the short term. I also would like to point out...
Keeping the great winning streak ratio alive. CEO is great here - knows about value. I quote from his shareholders letter: "...we believe our plans will help build significant shareholder value..." This means HI GUYS, BUY MY STOCK (lol) These guys have the FASTEST COVID antibody test kit on the market (10 minutes vs Becton Dickinson's 15 minute kit) - it is...
As of this writing the short float is around 77.46%. Stock is below 20 / 50 / 200 day moving averages & RSI looks like it's picking back up. Looks good for a move into $6/7 setting up for a short squeeze over the 200 EMA.
COVID-19 antibody test is a test intended for the qualitative detection (i.e., yes/no) of SARS-CoV-2 IgG antibodies in blood to identify individuals with an adaptive immune response to the virus that causes COVID-19